SOLID LIPID NANOPARTICLES: A REVIEW ON DIFFERENT TECHNIQUES AND APPROACHES TO TREAT BREAST CANCER
Keywords:Breast cancer, efficacy, multi-drug resistance, effective targeting, therapeutics, intracellular pathways.
Breast cancer, the most common malignancy among women, is also the second-leading cause of cancer deaths all over the world. As commonly used chemotherapy drugs, which are given systematically, causes toxicity not only to cancerous cells but also to proliferating normal cells. Similarly, drug resistance leads to drastic side effects and treatment failure. Thus arises the need for improving the therapeutic index of anticancer drugs. Owing to these failures, nanotechnology holds significant promises.
Supported literature was used to overcome these challenges, therapeutic drugs are encapsulated in nanoparticles. Concurrently, solid lipid nanoparticles (SLN) with their few merits like enhancing the therapeutic profile, overcoming multidrug resistance, providing a targeted approach, and serving as a controlled release have gained the attention of researchers. SLNs confine significant promises, overcome these challenges, and help to possibly deliver the drug to a specific part of the body, particular organ, or tissue by an actively or passively targeted delivery system, which will be beneficial in the diagnosis and treatment of breast cancer. The objective of this article is to highlight the factors that influence the targeted drug delivery system and resultant bioavailability and also provide updates on recent research and various approaches used for breast drug delivery systems.
Nounou MI, Elamrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast cancer: Conventional diagnosis and treatment modalities and recent patents and technologies supplementary issue: Targeted therapies in breast cancer treatment. Breast Cancer Basic Clin Res. 2015; 9(2):17-34.
Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles: Advanced Drug Delivery Reviews. 2007; 59(6):491-504.
Din FU, Aman W, Ullah I, Qureshi OS, Mustapha O, Shafique S, et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine. 2017; 12: 7291–309.
Gavas S, Quazi S, Karpiński TM. Nanoparticles for Cancer Therapy: Current Progress and Challenges. Nanoscale Res Lett [Internet]. 2021;16(1):173.
Cheng Yang S, Fang Lu L, Cai Y, Bi Zhu J, Wen Liang B, Zheng Yang C. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release. 1999; 59:299–307.
Güney G, Kutlu HM. Importance of solid lipid nanoparticles in cancer therapy. Technical Proceedings of the 2011 NSTI Nanotechnology Conference and Expo, NSTI-Nanotech 2011; 3: 400–3.
Hanahan D, Weinberg R. Hallmarks of Cancer: Supplement. Cell Press. 2011; 144 (5):646-74.
Bayón-Cordero L, Alkorta I, Arana L. Application of solid lipid nanoparticles to improve the efficiency of anticancer drugs. Nanomaterials. 2019; 9(3):474.
Yuko Nakamura, Ai Mochida, Peter L. Choyke HK. Nano-drug delivery: Is the enhanced permeability and retention (EPR) effect sufficient for curing cancer? Physiol Behav. 2016; 27 (10):2225-2238.
Makki J. Diversity of breast carcinoma: Histological subtypes and clinical relevance. Clin Med Insights Pathol. 2015; 8(1):23–31.
Das P, Das S, Jana A, Das TK. Demograph ic , clinico-pathological profile , and immunohistochemistry study in female breast cancer in eastern india : a hospital-based retrospective study. 2022;15(12):1–4.
Alfarouk KO, Stock CM, Taylor S, Walsh M, Muddathir AK, Verduzco D, et al. Resistance to cancer chemotherapy: Failure in drug response from ADME to P-gp. Cancer Cell Int. 2015;15(1):1–13.
Chorma A, Pargi AK, Yadav R. A comparative study of drainage of breast abscess by conventional incision and drainage versus suction drainage versus ultrasound-guided needle aspiration. 2022;15(11):15–7.
NAIR SS, VARKEY J. Isolation of Phytoconstituent, in Vitro Anticancer Study in Hela and Mcf-7 Cell Lines and Molecular Docking Studies of Pothos Scandens Linn. Int J Curr Pharm Res. 2021;13(5):42–51.
Callaghan R, Luk F, Bebawy M. Inhibition of the multidrug resistance P-glycoprotein: Time for a change of strategy? Drug Metab Dispos. 2014; 42(4):623–31.
Al-Akra L, Bae DH, Leck LYW, Richardson DR, Jansson PJ. The biochemical and molecular mechanisms involved in the role of tumor micro-environment stress in development of drug resistance. Biochim Biophys Acta - Gen Subj. 2019; (9):1390-1397.
Robey R, Dwyer A, Goldspiel B, Balis F, Tellingen O Van, Virginia W, et al. A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine.
Clin Cancer Res. 2009; 15(10): 3574–3582.
Nagai H, Kim YH. Cancer prevention from the perspective of global cancer burden patterns. J Thorac Dis. 2017; 9(3): 448–451.
Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol. 2005; 23(19):4265–74.
Guan SKY and J-L. Breast Cancer: Multiple Subtypes within a Tumor? Syn. Physiol Behav. 2017; 3 (11):753-760.
Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007; 9(5):1–14.
Wu J. The enhanced permeability and retention (Epr) effect: The significance of the concept and methods to enhance its application. J Pers Med. 2021;11(8);771-775.
Lu RM, Chen MS, Chang DK, Chiu CY, Lin WC, Yan SL, et al. Targeted Drug Delivery Systems Mediated by a Novel Peptide in Breast Cancer Therapy and Imaging. PLoS One. 2013; 8 (6):e66128.
Zhao Z, Ukidve A, Kim J, Mitragotri S. Targeting Strategies for Tissue-Specific Drug Delivery. Cell 2020; 181 (1):151-167.
Jahan S, Karim ME, Chowdhury EH. Nanoparticles targeting receptors on breast cancer for efficient delivery of chemotherapeutics. Biomedicines. 2021; 9(2):1–30.
De Jong WH, Borm PJA. Drug delivery and nanoparticles: Applications and hazards. Int J Nanomedicine. 2008; 3(2): 133–149.
Attia MF, Anton N, Wallyn J, Omran Z, Vandamme TF. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol. 2019;71(8):1185–98.
Tajbakhsh A, Hasanzadeh M, Rezaee M, Khedri M, Khazaei M, ShahidSales S, et al. Therapeutic potential of novel formulated forms of curcumin in the treatment of breast cancer by the targeting of cellular and physiological dysregulated pathways. J Cell Physiol. 2018; 233 (3):2183-2192.
Yu B, Tai HC, Xue W, Lee LJ, Lee RJ. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol. 2010; 27 (7):286-98.
Chang JM, Leung JWT, Moy L, Ha SM, Moon WK. Axillary nodal evaluation in breast cancer: State of the art. Radiology. 2020; 295(3):500–15.
Anatomy of the Breast, https://www.mskcc.org/cancer-care/types/breast/anatomy-breast.
Gabriel A. Breast Anatomy: Overview, Vascular Anatomy and Innervation of the Breast, Breast Parenchyma and Support Structures [Internet]. Medscape. 2016. Available from: https://reference.medscape.com/article/1273133-overview#showall.
Koo MM, von Wagner C, Abel GA, McPhail S, Rubin GP, Lyratzopoulos G. Typical and atypical presenting symptoms of breast cancer and their associations with diagnostic intervals: Evidence from a national audit of cancer diagnosis. Cancer Epidemiol 2017; 48:140–6.
Kontermann RE. Immunoliposomes for cancer therapy. Current Opinion in Molecular Therapeutics. 2006; 8 (1):39-45.
Sever R, Brugge JS. Genetic and epigenetic mechanisms of cancer progression. Cold Spring Harb Perspect Med. 2015; 5 (4):a006098.
Li X, Zhou J, Xiao M, Zhao L, Zhao Y, Wang S, et al. Uncovering the Subtype-Specific Molecular Characteristics of Breast Cancer by Multiomics Analysis of Prognosis-Associated Genes, Driver Genes, Signaling Pathways, and Immune Activity. Front Cell Dev Biol. 2021; 9:1–13.
Wesolowski R, Ramaswamy B. Gene expression profiling: Changing face of breast cancer classification and management. Gene Expr. 2018; 15(3):105–15.
Therese Sørliea,b,c, Charles M. Peroua,d, Robert Tibshiranie, Turid Aasf, Stephanie Geislerg, Hilde Johnsenb, Trevor Hastiee, Michael B. Eisenh, Matt van de Rijni, Stefanie S. Jeffreyj, Thor Thorsenk, Hanne Quistl, John C. Matesec P. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98 (19):10869-74.
Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015; 5 (10):2929-43.
Strehl JD, Wachter DL, Fasching PA, Beckmann MW, Hartmann A. Invasive breast cancer: Recognition of molecular subtypes. Breast Care. 2011; 6(4): 258–264.
Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014; 5(3): 412–424.
Xinyi Luo, Yang Lia, Zhenglai Hua, Xiaoxia Xue X, Wang, Mingshi Pang, Cheng Xiao, Hongyan Zhao, Aiping Lyu YL. Exosomes-mediated tumor metastasis through reshaping tumor microenvironment and distant niche - ScienceDirect. 2023. p. 327–36.
Ekyalongo RC, Yee D. Revisiting the IGF-1R as a breast cancer target. npj Precis Oncol. 2017;1(1):1–6.
Jr FM and DJJ. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol. 2009; 63 (4):571-82.
Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of cancer drug resistance: A brief review. Adv Pharm Bull. 2017;7(3):339–48.
Moo TA, Sanford R, Dang C, Morrow M. Overview of Breast Cancer Therapy. PET Clin. 2018 ;13(3):339–54.
Tiwari G, Tiwari R, Bannerjee S, Bhati L, Pandey S, Pandey P, et al. Drug delivery systems: An updated review. Int J Pharm Investig. 2012; 2(1):2.
Glassman PM, Muzykantov VR. Pharmacokinetic and pharmacodynamic properties of drug delivery systems. J Pharmacol Exp Ther. 2019; 370(3):570–80.
Ayesha Khalid, Stefano Persano, Haifa Shen, Yuliang Zhao, Elvin Blanco, Mauro Ferrari, and JW. Strategies for improving drug delivery: Nanocarriers and microenvironmental priming. Physiol Behav. 2017, 14(7):865–877.
Dr. Rong Yang, Dr. Tuo Wei, Hannah Goldberg, Dr. Weiping Wang, Dr. Kathleen Cullion and P. Getting Drugs across Biological Barriers. Adv Mater. 2017; 29(37):1–54.
Kiptoo P, Calcagno AM, Siahaan TJ. Physiological, Biochemical, and Chemical Barriers to Oral Drug Delivery. Drug Delivery: Principles and Applications: Second Edition. 2016; 19–34.
Golombek SK, May J, Theek B, Appold L. Tumor Targeting via EPR: Strategies to Enhance Patient Responses. Adv Drug Deliv Rev. 2018;130;17–38.
Vasir J, Reddy M, Labhasetwar V. Nanosystems in Drug Targeting: Opportunities and Challenges. Curr Nanosci. 2006;1(1):47–64.
Tewabe A, Abate A, Tamrie M, Seyfu A, Siraj EA. Targeted drug delivery — from magic bullet to nanomedicine: Principles, challenges, and future perspectives. J Multidiscip Healthc. 2021 ;14:1711–24.
Bazak R, Houri M, Achy SEL, Hussein W, Refaat T. Passive targeting of nanoparticles to cancer : A comprehensive review of the literature. Mol Clin Onco. 2014; 2 (6):904-908.
Tajbakhsh A, Hasanzadeh M, Rezaee M, Khedri M, Khazaei M, ShahidSales S, et al. Therapeutic potential of novel formulated forms of curcumin in the treatment of breast cancer by the targeting of cellular and physiological dysregulated pathways. J Cell Physiol. 2018; 233(3):2183–92.
Guorgui J, Wang R, Mattheolabakis G, Mackenzie GG. Curcumin formulated in solid lipid nanoparticles has enhanced efficacy in Hodgkin’s lymphoma in mice. Archives of Biochemistry and Biophysics. 2018; 648:12-19.
Clemente N, Ferrara B, Gigliotti CL, Boggio E, Capucchio MT, Biasibetti E, et al. Solid lipid nanoparticles carrying temozolomide for melanoma treatment. Preliminary in vitro and in vivo studies. Int J Mol Sci. 2018; 19 (2):255.
Shah MK, Madan P, Lin S. Preparation, in vitro evaluation and statistical optimization of carvedilol-loaded solid lipid nanoparticles for lymphatic absorption via oral administration. Pharm Dev Technol. 2014; 19(4):475–85.
Sinha R. Chronic Stress, Drug Use, and Vulnerability to Addiction Rajita. Bone. Ann N Y Acad Sci. 2008; 1141: 105–130.
Muller WA. Getting Leukocytes to the Site of Inflammation. Bone.
Vet Pathol. 2013; 50(1): 7–22.
Maeda H. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Japan Acad Ser B Phys Biol Sci. 2012;88(3):53–71.
Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018; 9:1410.
Subhan MA, Yalamarty SSK, Filipczak N, Parveen F, Torchilin VP. Recent advances in tumor targeting via epr effect for cancer treatment. J Pers Med. 2021; 11 (6):571.
Lee MK, Lim SJ, Kim CK. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials. 2007; 28(12):2137–46.
Ficai A, Grumezescu AM. Nanostructures for cancer therapy. Nanostructures for Cancer Therapy. 2017; 1–882
Yingchoncharoen P, Kalinowski DS, Richardson DR. Lipid-based drug delivery systems in cancer therapy: What is available and what is yet to come. Pharmacol Rev. 2016; 68(3):701–87.
Zhao Y, Huan ML, Liu M, Cheng Y, Sun Y, Cui H, et al. Doxorubicin and resveratrol co-delivery nanoparticle to overcome doxorubicin resistance. Sci Rep. 2016;6:1–15.
Allen TM, Cullis PR. Drug Delivery Systems: Entering the Mainstream. Science. 2004; 303(5665):1818–22.
Baas J, Senninger N, Elser H. The reticuloendothelial system. An overview of function, pathology and recent methods of measurement. Z Gastroenterol. 1994; 32 (2):117-23.
Colino CI, Lanao JM, Gutierrez-Millan C. Targeting of Hepatic Macrophages by Therapeutic Nanoparticles. Front Immunol. 2020; 11: 218.
Wang L, Hu C, Shao L. The-antimicrobial-activity-of-nanoparticles--present-situati. Int J Nanomedicin. 2017;12:1227–49.
Stolnik S, Daudali B, Arien A, Whetstone J, Heald CR, Garnett MC, et al. The effect of surface coverage and conformation of poly(ethylene oxide) (PEO) chains of poloxamer 407 on the biological fate of model colloidal drug carriers. Biochim Biophys Acta - Biomembr. 2001 ;1514(2):261–79.
Singh S, Kushwaha AK, Vuddanda PR, Karunanidhi P, Singh SK. Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability. Biomed Res Int. 2013: 584549.
Preta G. New Insights Into Targeting Membrane Lipids for Cancer Therapy. Front Cell Dev Biol. 2020; 8:1–10.
Gocheva G, Ivanova A. A Look at Receptor-Ligand Pairs for Active-Targeting Drug Delivery from Crystallographic and Molecular Dynamics Perspectives. Mol Pharm. 2019;16(8):3293–321.
Nishioka Y, Yoshino H. Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev. 2001;47(1):55–64.
Bhagwat GS, Athawale RB, Gude RP, Md S, Alhakamy NA, Fahmy UA, et al. Formulation and Development of Transferrin Targeted Solid Lipid Nanoparticles for Breast Cancer Therapy. Front Pharmacol. 2020;111–12.
Xu S, Olenyuk BZ, Okamoto CT, Hamm-Alvarez SF. Targeting receptor-mediated endocytotic pathways with nanoparticles: Rationale and advances. Advanced Drug Delivery Reviews. 2013; 65 (1):121-38.
Lu B, Xiong S Bin, Yang H, Yin XD, Chao RB. Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases. Eur. J Pharm Sci. 2006; 28 (1-2):86-95.
Shulpekova Y, Nechaev V, Kardasheva S, Sedova A, Kurbatova A, Bueverova E, et al. The concept of folic acid in health and disease. Molecules. 2021;26(12):1–29.
Cheung A, Bax HJ, Josephs DH, Ilieva KM, Pellizzari G, Opzoomer J, et al. Targeting folate receptor alpha for cancer treatment. Oncotarget. 2016;7(32):52553–74.
Dharap SS, Wang Y, Chandna P, Khandare JJ, Qiu B, Gunaseelan S, et al. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci U S A. 2005;102(36):12962–7.
Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev. 2002; 54 (5):675-93.
Goldstein JL, Anderson RG, Brown MS. Receptor-mediated endocytosis and the cellular uptake of low density lipoprotein. Ciba Foundation symposium. 1982;77–95.
Yingchoncharoen P, Kalinowski DS, Richardson DR. Lipid-based drug delivery systems in cancer therapy: What is available and what is yet to come. Pharmacol Rev. 2016; 68(3):701–87.
Campion O, Al Khalifa T, Langlois B, Thevenard-Devy J, Salesse S, Savary K, et al. Contribution of the Low-Density Lipoprotein Receptor Family to Breast Cancer Progression. Front Oncol. 2020; 1–9.
Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003; 24(4):389–427.
Svensen N, Walton JGA, Bradley M. Peptides for cell-selective drug delivery. Trends Pharmacol Sci. 2012;33(4):186–92.
Tan LTH, Chan KG, Pusparajah P, Lee WL, Chuah LH, Khan TM, et al. Targeting membrane lipid a potential cancer cure? Front Pharmacol. 2017;8(12):1–6.
Casares D, Escribá P V., Rosselló CA. Membrane lipid composition: Effect on membrane and organelle structure, function and compartmentalization and therapeutic avenues. Int J Mol Sci. 2019; 20 (9):2167.
Zalba S,Timo L.M.,ten Hagen T. Cell membrane modulation as adjuvant in cancer therapy. Cancer Treat. Rev. 2017; 52: 48-57.
Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. B Cells and Antibodies - Molecular Biology of the Cell - NCBI Bookshelf.Molecular Biology of the Cell. 2002.
Leth-Larsen R, Lund RR, Ditzel HJ. Plasma membrane proteomics and its application in clinical cancer biomarker discovery. Mol Cell Proteomics. 2010; 9(7):1369–82.
Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006; 66(13):6732–40.
Santos M, Butel JS. Detection of a complex of SV40 large tumor antigen and 53K cellular protein on the surface of SV40‐transformed mouse cells. J Cell Biochem. 1982;19(2):127–44.
Yu B, Tai HC, Xue W, Lee LJ, Lee RJ. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol. 2010; 27(7):286–98.
Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics. 2012;2(1):3–44.
Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J. 2018; 26(1):64–70.
Manasi D, Chandana M, Sanjeeb K. Ligand-based targeted therapy for cancer tissue. Expert Opin Drug Deliv [Internet]. 2009; 6(3):285–304.
Zwicke GL, Mansoori GA, Jeffery CJ. Targeting of Cancer Nanotherapeutics. Nano Rev. 2012;1:1–11.
Christensen E, Henriksen JR, Jørgensen JT, Amitay Y, Shmeeda H, Gabizon AA, et al. Folate receptor targeting of radiolabeled liposomes reduces intratumoral liposome accumulation in human KB carcinoma xenografts. Int J Nanomedicine. 2018;13:7647–56.
Ebbing M, Bønaa KH, Nygård O, Arnesen E, Ueland PM, Nordrehaug JE, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA - J Am Med Assoc. 2009;302(19):2119–26.
Ghazarian H, Idoni B, Oppenheimer SB. A glycobiology review: Carbohydrates, lectins and implications in cancer therapeutics. Acta Histochem. 2011;113(3):236–47.
Sicard JF, Bihan G Le, Vogeleer P, Jacques M, Harel J. Interactions of intestinal bacteria with components of the intestinal mucus. Front Cell Infect Microbiol. 2017;7:387.
Aparicio LA, Calvo MB, Figueroa A, Pulido EG, Campelo RG. Potential role of sugar transporters in cancer and their relationship with anticancer therapy. Int J Endocrinol. 2010; 1687-8337.
Varki A. Biological roles of glycans. Glycobiology. 2017;27(1):3–49.
Yau T, Dan X, Ng CCW, Ng TB. Lectins with potential for anti-cancer therapy. Molecules. 2015;20(3):3791–810.
Jiang Z, Li T, Cheng H, Zhang F, Yang X, Wang S, et al. Nanomedicine potentiates mild photothermal therapy for tumor ablation. Asian J Pharm Sci. 2021;16(6):738–61.
Van de Sande L, Cosyns S, Willaert W, Ceelen W. Albumin-based cancer therapeutics for intraperitoneal drug delivery: a review. Drug Deliv [Internet]. 2020; 27(1):40–53.
Shibuya M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes and Cancer. 2011;2(12):1097–105.
Christian CA, Moenter SM. Vasoactive intestinal polypeptide can excite gonadotropin-releasing hormone neurons in a manner dependent on estradiol and gated by time of day. Endocrinology. 2008;149:3130–6.
Lichtenstein M, Zabit S, Hauser N, Farouz S, Melloul O, Hirbawi J, et al. Tat for enzyme/protein delivery to restore or destroy cell activity in human diseases. Life. 2021;11(9):924.
Marqus S, Pirogova E, Piva TJ. Evaluation of the use of therapeutic peptides for cancer treatment. J Biomed Sci. 2017;24(1):1–15.
Parray HA, Shukla S, Samal S, Shrivastava T, Ahmed S. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ’ s public news and information . 2020.
John P Manis. Overview of therapeutic monoclonal antibodies - 2022 Jul 1:1-18.
Rajesh S, Jr. JWL. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009; 86 (3):215-23.
Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1–3.
Songara NS, Bhargava AK, Chaudhary A, Sharma A. Assessment of Magnesium (Mg) and Zinc (Zn) in Carcinoma Breast Patients. Asian J Pharm Clin Res. 2022;15(10):159–62.
Price PM, Mahmoud WE, Al-Ghamdi AA, Bronstein LM. Magnetic drug delivery: Where the field is going. Front Chem. 2018;6;1 –7.
Yao J, Feng J, Chen J. External-stimuli responsive systems for cancer theranostic. Asian J Pharm Sci [Internet]. 2016;11(5):585–95. Available from: http://dx.doi.org/10.1016/j.ajps.2016.06.001
Wang X, Liu S, Sun Y, Yu X, Lee SM, Cheng Q, et al. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat Protoc. 2022;1-30.
Maeda H. Enhanced permeability and retention effect [Internet]. Wikipedia. 2021. Available from: https://en.wikipedia.org/wiki/Enhanced_permeability_and_retention_effect
Giang I, Boland EL, Poon GMK. Prodrug applications for targeted cancer therapy. AAPS J. 2014;16(5):899–913.
Uprety B, Abrahamse H. Targeting Breast Cancer and Their Stem Cell Population through AMPK Activation: Novel Insights. Cells. 2022;11(3).
Yang J, Griffin A, Qiang Z, Ren J. Organelle-targeted therapies: a comprehensive review on system design for enabling precision oncology. Signal Transduct Target Ther. 2022;7(1).
Parker CL, Mcsweeney MD, Lucas AT, Jacobs TM, Wadsworth D, Zamboni WC, et al. Pretargeted delivery of PEG-coated drug carriers to breast tumors using multivalent, bispecific antibody against polyethylene glycol and HER2. Nanomedicine. 2020;21:(102076.):1–18.
Hye JY, Cho YH, Moon Y, Young WP, Yoon HK, Kim YJ, et al. Transcriptional targeting of gene expression in breast cancer by the promoters of protein regulator of cytokinesis 1 and ribonuclease reductase 2. Exp Mol Med. 2008;40(3):345–53.
How to Cite
Copyright (c) 2022 SHILPA A. GAJBHIYE, MORESHWAR P. PATIL
This work is licensed under a Creative Commons Attribution 4.0 International License.